A Biosynthetic Strategy to Manufacture Less Toxic Amphotericins
生产毒性较小的两性霉素的生物合成策略
基本信息
- 批准号:10383158
- 负责人:
- 金额:$ 2.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2022-07-31
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAmphotericinAmphotericin BAnabolismAntifungal AgentsArtemisininsBackBreathingCellsChemistryClinicalComplexConsumptionCouplingDevelopmentDirected Molecular EvolutionDose-LimitingElderlyEngineeringEnzymesEvolutionExcisionGene ClusterGoalsGuanosine Diphosphate SugarsHomology ModelingHydrolaseHydrolysisImmune systemIndustrializationInfectionKnowledgeLearningLifeMalariaMalignant NeoplasmsMedicalMedicineMentorsMethodologyMicrobeModificationMoldsMycosesNatural ProductsNatureNew AcceptorsNucleotidesPathway interactionsPatientsPersonsPharmaceutical PreparationsPharmacologic SubstancePolyenesProcessProductionProtein BiosynthesisReactionResistanceResourcesRouteScienceSite-Directed MutagenesisStructureStructure-Activity RelationshipTemperatureThermodynamicsTimeToxic effectTrainingTuberculosisVariantWaterWorkanalogbasecareer developmentcatalystchemical synthesiscost effectivedesigneffective therapyenzyme pathwayflexibilityglycosyltransferaseimprovedinnovationmetabolic engineeringmutantmycosaminenucleotidyltransferasepressurepreventprotein structureprototypescaffoldskillssmall moleculesuccesssugarundergraduate student
项目摘要
PROJECT ABSTRACT
Amphotericin B is a powerful antifungal treatment however, widespread use is prevented by dose limiting toxicity.
Nontoxic analogs have been discovered but their structural complexity precludes a practical chemical synthesis
on industrial scale. Microbes are extraordinarily adept at producing amphotericin, as metric tons are fermented
annually. Enzymes found within amphotericin’s natural biosynthetic pathway can serve as exceptionally specific
and renewable biocatalysts that can overcome many common limitations encountered during its chemical
synthesis. Reimagining aspects of amphotericin’s biosynthesis could therefore produce a robust and sustainable
path to these nontoxic variants. This proposal aims to develop a deep understanding of several catalytic
processes involved in amphotericin’s natural biosynthesis. Harnessing this knowledge, key enzymes and
biosynthetic pathways will be evolved and engineered to construct a biosynthetic strategy to manufacture less
toxic amphotericins. Cell-free protein synthesis provides a means to prototype these enzymes and pathways in
a quantitative and high-throughput manner. Ultimately this work is expected to be an efficient platform to create
new, best-in-class antifungal candidates, provide probes to interrogate structure-activity relationships dictating
AmB’s potency and toxicity, and drive the continued development of enzymes as renewable, ecologically-safe
and flexible biocatalysts for pharmaceutical sciences. The proposal provides ample opportunities for me to build
on the knowledge from my undergraduate and graduate studies so I may continue to learn, innovate, and develop
skills to be a well-rounded scientific leader. Based on the unique scientific expertise and mentoring track record
of my Sponsor and Cosponsor, they are the ideal pair to provide constructive guidance in science and career
development, and maximize my potential to drive this project towards success.
项目摘要
两性霉素B是一种有效的抗真菌治疗药物,但由于剂量限制性毒性而无法广泛使用。
已经发现了无毒的类似物,但是它们的结构复杂性排除了实际的化学合成
工业规模。微生物非常善于生产抗生素,因为公吨发酵
每年。在阿氏菌素的天然生物合成途径中发现的酶可以作为异常特异性的
和可再生生物催化剂,可以克服其化学过程中遇到的许多常见限制
合成.因此,重新构想两性霉素的生物合成方面可以产生强大且可持续的
找到这些无毒变异体的途径该建议旨在深入了解几种催化剂
这是一个涉及到植物素天然生物合成的过程。利用这些知识,关键酶和
生物合成途径将被进化和改造,以构建一种生物合成策略,
有毒的抗生素无细胞蛋白质合成提供了一种手段,原型这些酶和途径,
定量和高通量的方式。最终,这项工作有望成为一个有效的平台,
新型、一流的抗真菌候选药物,提供探针来询问结构-活性关系,决定
AmB的效力和毒性,并推动酶作为可再生的,生态安全的酶的持续发展
和制药科学的柔性生物催化剂。该提案为我提供了充分的机会,
在本科和研究生学习的基础上,我可以继续学习,创新和发展
成为一名全面的科学领导者的技能。基于独特的科学专业知识和指导记录,
作为我的赞助人和共同赞助人,他们是在科学和职业方面提供建设性指导的理想伴侣。
发展,并最大限度地发挥我的潜力,推动这个项目走向成功。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jonathan Webb Bogart其他文献
Jonathan Webb Bogart的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
有機分子触媒を用いたAmphotericin Bの合成研究
有机分子催化剂合成两性霉素B的研究
- 批准号:
24K17671 - 财政年份:2024
- 资助金额:
$ 2.45万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
EnLAmB - Enabling global access to affordable generic liposomal amphotericin B injectable formulations via advanced manufacturing technology
EnLAmB - 通过先进的制造技术,使全球能够获得负担得起的通用脂质体两性霉素 B 注射制剂
- 批准号:
MR/X014010/1 - 财政年份:2023
- 资助金额:
$ 2.45万 - 项目类别:
Research Grant
Integrating genome-wide association study, quantitative trait loci mapping and transcriptome sequencing to identify genes associated with amphotericin B resistance in Aspergillus fumigatus
整合全基因组关联研究、数量性状基因座作图和转录组测序,鉴定与烟曲霉两性霉素 B 耐药性相关的基因
- 批准号:
559052-2021 - 财政年份:2022
- 资助金额:
$ 2.45万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Study on naturally-occurring peptides potentiating amphotericin B activity
天然存在的肽增强两性霉素 B 活性的研究
- 批准号:
22K05333 - 财政年份:2022
- 资助金额:
$ 2.45万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Integrating genome-wide association study, quantitative trait loci mapping and transcriptome sequencing to identify genes associated with amphotericin B resistance in Aspergillus fumigatus
整合全基因组关联研究、数量性状基因座作图和转录组测序,鉴定与烟曲霉两性霉素 B 耐药性相关的基因
- 批准号:
559052-2021 - 财政年份:2021
- 资助金额:
$ 2.45万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Amphotericin B Restoration of Anion Secretion in Cystic Fibrosis Airways
两性霉素 B 恢复囊性纤维化气道阴离子分泌
- 批准号:
10024667 - 财政年份:2020
- 资助金额:
$ 2.45万 - 项目类别:
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections
NH101的开发:一种简单高效的门诊干粉两性霉素B-DryNeb(干粉雾化器),用于治疗敏感和多重耐药曲霉菌/真菌感染
- 批准号:
9909193 - 财政年份:2020
- 资助金额:
$ 2.45万 - 项目类别:
Amphotericin B Restoration of Anion Secretion in Cystic Fibrosis Airways
两性霉素 B 恢复囊性纤维化气道阴离子分泌
- 批准号:
10248529 - 财政年份:2020
- 资助金额:
$ 2.45万 - 项目类别:
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections
NH101的开发:一种简单高效的门诊干粉两性霉素B-DryNeb(干粉雾化器),用于治疗敏感和多重耐药曲霉菌/真菌感染
- 批准号:
10484014 - 财政年份:2020
- 资助金额:
$ 2.45万 - 项目类别:
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections
NH101的开发:一种简单高效的门诊干粉两性霉素B-DryNeb(干粉雾化器),用于治疗敏感和多重耐药曲霉菌/真菌感染
- 批准号:
10654834 - 财政年份:2020
- 资助金额:
$ 2.45万 - 项目类别: